UPDATE 4-AstraZeneca suffers another setback as it halts volrustomig lung cancer trial

* Volrustomig combination found unlikely to meet main goals * Company also reports positive readouts from two other late-stage lung cancer trials * Other Phase III volrustomig trials to continue as

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)